Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 11/20 | 0.47 |
| ▸ | TNK2 | Q07912 | 5/20 | 0.39 |
| ▸ | EGFR | P00533 | 3/20 | 0.38 |
| ▸ | TEC | P42680 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | BMX | P51813 | 2/20 | 0.37 |
| ▸ | ITK | Q08881 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | FASN | P49327 | 1/20 | 0.36 |
| ▸ | TRPC6 | Q9Y210 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30289617 | 0.92 | BTK (0.40) | BTKTNK2EGFRTECPOLB | |
| SCHEMBL30289626 | 0.91 | BTK (0.43) | BTKTNK2POLBNPSR1 | |
| SCHEMBL30289648 | 0.87 | TNK2 (0.45) | BTKTNK2EGFRTECPOLB | |
| SCHEMBL30289587 | 0.85 | BTK (0.48) | BTKTNK2POLBNPSR1 | |
| SCHEMBL30289599 | 0.85 | BTK (0.48) | BTKTNK2POLBNPSR1 | |
| SCHEMBL30289682 | 0.84 | TNK2 (0.43) | TNK2 | |
| SCHEMBL30289800 | 0.83 | TNK2 (0.38) | BTKTNK2POLBNPSR1 | |
| SCHEMBL30289721 | 0.83 | BTK (0.40) | BTKTNK2POLBNPSR1 | |
| SCHEMBL30289731 | 0.81 | TNK2 (0.39) | TNK2POLBNPSR1 | |
| SCHEMBL30289697 | 0.80 | TNK2 (0.49) | BTKTNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115894497-A | Imidazopyrimidine compounds, and preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2023-04-04 | — | — | CN | disclosed |